Alto Neuroscience Promotes Nick Smith to President and CFO

Alto Neuroscience Inc., a clinical-stage biopharmaceutical company developing novel precision medicines for neuropsychiatric disorders, has promoted Nick Smith to President and Chief Financial Officer.

Smith will continue to lead Alto’s finance function and oversee corporate strategy and business development, reporting to Amit Etkin, M.D., Ph.D., Alto’s founder, Chief Executive Officer and chair of the board of directors.

“Nick has been an exceptional partner in building Alto and has played a central role in the strategic and financial actions that have positioned the company for its next stage,” said Etkin. “This promotion recognizes the breadth of his leadership and formalizes the role he already plays as we advance ALTO-207 and the broader pipeline.”

Experience

Smith joined Alto in 2021 as chief business officer and has served as Chief Financial Officer since 2022. During his tenure, he has led Alto’s corporate development and capital strategy, including the company’s initial public offering, the acquisition of ALTO-207 in May 2025 and subsequent financings supporting the program’s development.